NRG
JAZZ icon

Nemes Rush Group’s Jazz Pharmaceuticals JAZZ Stock Holding History

Nemes Rush Group’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$241 Hold
1
– – ﹤0.01% 935
2026
Q1 		$189 Sell
1
-1
-50% -$175 ﹤0.01% 921
2025
Q4 		$340 Buy
+2
New +$307 ﹤0.01% 903

Other funds holding JAZZ

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Nemes Rush Group's JAZZ Position: Q2 2026 in Review

Nemes Rush Group held its Jazz Pharmaceuticals (JAZZ) position steady in Q2 2026 at 1 share worth $241. The position accounts for ﹤0.01% of the portfolio, ranked #935.

Nemes Rush Group first reported a position in JAZZ in Q4 2025 and has held it in 3 quarters since. The position peaked at $340 in Q4 2025. 646 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.

  • Nemes Rush Group held 1 share of Jazz Pharmaceuticals worth $241 as of Q2 2026.
  • Nemes Rush Group left its Jazz Pharmaceuticals share count unchanged in Q2 2026.
  • Jazz Pharmaceuticals made up ﹤0.01% of Nemes Rush Group's portfolio in Q2 2026, its #935 holding.
  • Nemes Rush Group first reported a position in Jazz Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Nemes Rush Group's Jazz Pharmaceuticals position peaked at $340 in Q4 2025.
  • 646 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.

Based on Nemes Rush Group's 13F filing for Q2 2026, filed 14 Aug 2026.